Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis

Lung Cancer

Volumn 90, Issue 2, 2015, Pages 255-260

  Chiari, Rita ^a   Metro, Giulio ^a   Iacono, Daniela ^b   Bellezza, Guido ^c   Rebonato, Alberto ^c   Dubini, Alessandra ^d   Sperduti, Isabella ^e   Bennati, Chiara ^a   Paglialunga, Luca ^a   Burgio, Marco Angelo ^f   Baglivo, Sara ^a   Giusti, Raffaele ^b   Minotti, Vincenzo ^a   Delmonte, Angelo ^f   Crinò, Lucio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Alectinib; ALK; ALK TKI; Ceritinib; Crizotinib; Non small cell lung cancer

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; TREATMENT DURATION; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; METABOLISM; MULTICENTER STUDY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84955293624     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.09.009     Document Type: Article

References (28)

1. Califano R., Abidin A., Tariq N.U., Economopoulou P., Metro G., Mountzios G. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treat. Rev. 2015, 41:401-411.
2. Dancey J.E., Bedard P.L., Onetto N., Hudson T.J. The genetic basis for cancer treatment decisions. Cell 2012, 148:409-420.
3. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
4. Roskoski R. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol. Res. 2013, 68:68-94.
5. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008, 14:4275-4283.
6. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008, 68:3389-3395.
7. Gainor J.F., Varghese A.M., Ou S.H., Kabraji S., Awad M.M., Katayama R., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19:4273-4281.
8. Malik S.M., Maher V.E., Bijwaard K.E., Becker R.L., Zhang L., Tang S.W., et al. U.S. food and drug administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin. Cancer Res. 2014, 20:2029-2034.
9. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., et al. First-line crizotinib versus chmoetherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371:2167-2177.
10. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 370:1189-1197.
11. ALEX study: a Randomized, phase III study comparing alectinib with crizotinib in treatment-naive anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients. Available at: (accessed 15.08.15). http://https://clinicaltrials.gov/ct2/results%3Fterm=NCT02075840&Search=Search.
12. Weickhardt A.J., Scheier B., Burke J.M., Gan G., Lu X., Bunn P.A., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol. 2012, 7:1807-1814.
13. Ou S.H., Jänne P.A., Bartlett C.H., Tang Y., Kim D.W., Otterson G.A., et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann. Oncol. 2014, 25:415-422.
14. Gainor J.F., Tan D.S., De Pas T., Solomon B.J., Ahmad A., Lazzari C., et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin. Cancer Res. 2015, 21:2745-2752.
15. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin. Roentgenol. 2005, 40:90-97.
16. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009, 27:4247-4253.
17. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
18. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
19. Kim D.W., Ahn M.J., Shi Y., De Pas T.M., Yang P.C., Riely G.J., et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2012, 30(suppl):7533. (abstract).
20. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. Med. 2013, 368:2385-2394.
21. Felip E., Kim D.W., Mehra R., Tan D.S.W., Chow L.Q.M., Camidge D.R., et al. Efficacy and safety of ceritinib in patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Ann. Oncol. 2014, 90:S33-S34. (abstract).
22. Felip E., Orlov S., Park K., et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2015, 33(suppl):8060. (abstract).
23. Mok T., Spigel D., Felip E., De Marinis F., Ahn M., Groen H.J.M., et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J. Clin. Oncol. 2015, 33(suppl):8059. (abstract).
24. Ou S.H., Ahn J.S., De Petris L., Govindan R., Yang J.C.H., Hughes B., et al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J. Clin. Oncol. 2015, 33(suppl):8008. (abstract).
25. Browning E.T., Weickhardt A.J., Camidge D.R. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J. Thorac. Oncol. 2013, 8:e21.
26. Matsuoka H., Kurata T., Okamoto I., Kaneda H., Tanaka K., Nakagawa K. Clinical response to crizotinib retreatment after acquisition of drug resistance. J. Clin. Oncol. 2013, 31:e322-e323.
27. LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib. Available at: (accessed 15.08.15). http://https://clinicaltrials.gov/ct2/results%3Fterm=NCT01828112&Search=Search.
28. Steuer C.E., Ramalingam S.S. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer 2014, 120:2392-2402.